Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556785 | 0.84 | P2RX7 (0.38) | ALDH1A1TP53KCNA5MAPT | |
| SCHEMBL5561542 | 0.79 | KCNA5 (0.41) | SMN1; SMN2KCNA5NPC1 | |
| SCHEMBL5556045 | 0.77 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2PKMHTTTP53 | |
| SCHEMBL5561822 | 0.76 | LMNA (0.40) | ALDH1A1SMN1; SMN2LMNAKCNA5 | |
| SCHEMBL5562516 | 0.76 | FAAH (0.40) | ALDH1A1SMN1; SMN2HTTLMNAMAPT | |
| SCHEMBL5562246 | 0.76 | KCNA5 (0.40) | ALDH1A1SMN1; SMN2HTTTP53LMNA | |
| SCHEMBL5556632 | 0.76 | MAPT (0.40) | ALDH1A1SMN1; SMN2PKMHTTTP53 | |
| SCHEMBL5561753 | 0.76 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAMAPTNPC1 | |
| SCHEMBL5562392 | 0.76 | MAPT (0.47) | ALDH1A1SMN1; SMN2TP53LMNAKCNA5 | |
| SCHEMBL5562363 | 0.75 | MEN1 (0.40) | ALDH1A1SMN1; SMN2PKMHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631296-B1 | 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-7060698-B2 | Benzoxazepinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | HOFFMANN-LA ROCHE INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | BACE1, BACE2, PSEN1 | ALDH1A1 724/4885SMN1; SMN2 2144/4885PKM 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.